{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:52:20Z","timestamp":1787496740046,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"EU Gilead Research Scholars Program","award":["2020 BP 00046"],"award-info":[{"award-number":["2020 BP 00046"]}]},{"DOI":"10.13039\/501100003030","name":"Catalan Agency of Management of University and Research Grants","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Persistence of viral reservoirs has been observed in people with human immunodeficiency virus (HIV), despite long-term antiretroviral therapy (ART), and likely contributes to chronic immune activation and inflammation. Obefazimod is a novel drug that inhibits human immunodeficiency virus type 1 (HIV-1) replication and reduces inflammation. Here we assess whether obefazimod is safe and might impact HIV-1 persistence, chronic immune activation, and inflammation in ART-suppressed people with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated obefazimod-related adverse events, changes in cell-associated HIV-1 DNA and RNA, residual viremia, immunophenotype, and inflammation biomarkers in blood and rectal tissue. We compared 24 ART-suppressed people with HIV who received daily doses of 50 mg obefazimod for 12 weeks (n = 13) or 150 mg for 4 weeks (n = 11) and 12 HIV-negative individuals who received 50 mg for 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 50- and 150-mg doses of obefazimod were safe, although the 150-mg dose showed inferior tolerability. The 150-mg dose reduced HIV-1 DNA (P = .008, median fold change = 0.6) and residual viremia in all individuals with detectable viremia at baseline. Furthermore, obefazimod upregulated miR-124 in all participants and reduced the activation markers CD38, HLA-DR, and PD-1 and several inflammation biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The effect of obefazimod by reducing chronic immune activation and inflammation suggests a potential role for the drug in virus remission strategies involving other compounds that can activate immune cells, such as latency-reversing agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiad251","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T08:00:30Z","timestamp":1688371230000},"page":"1280-1291","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy"],"prefix":"10.1093","volume":"228","author":[{"given":"Silvia","family":"Bernal","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"Department of Infectious Diseases and Immunity, School of Medicine, University of Vic\u2013Central University of Catalonia , Vic , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Puertas","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mor\u00f3n-L\u00f3pez","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D","family":"Cranston","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Urrea","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Dalmau","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Salgado","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Germans Trias i Pujol Research Institute , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"G\u00e1lvez","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Erkizia","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McGowan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Scherrer","sequence":"additional","affiliation":[{"name":"Abivax , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Revollo","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita contra les Infeccions , Badalona , Spain"},{"name":"Department of Infectious Diseases, University Hospital Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Sirera","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita contra les Infeccions , Badalona , Spain"},{"name":"Department of Infectious Diseases, University Hospital Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Santos","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita contra les Infeccions , Badalona , Spain"},{"name":"Department of Infectious Diseases, University Hospital Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"Department of Infectious Diseases and Immunity, School of Medicine, University of Vic\u2013Central University of Catalonia , Vic , Spain"},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Fundaci\u00f3 Lluita contra les Infeccions , Badalona , Spain"},{"name":"Department of Infectious Diseases, University Hospital Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"Department of Infectious Diseases and Immunity, School of Medicine, University of Vic\u2013Central University of Catalonia , Vic , Spain"},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Fundaci\u00f3 Lluita contra les Infeccions , Badalona , Spain"},{"name":"Department of Infectious Diseases, University Hospital Germans Trias i Pujol , Badalona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"Department of Infectious Diseases and Immunity, School of Medicine, University of Vic\u2013Central University of Catalonia , Vic , Spain"},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Germans Trias i Pujol Research Institute , Badalona , Spain"},{"name":"Catalan Institution for Research and Advanced Studies , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"2023110719165154200_jiad251-B1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/QAD.0b013e328353f3f1","article-title":"HIV reservoirs: pathogenesis and obstacles to viral eradication and cure","volume":"26","author":"Chun","year":"2012","journal-title":"AIDS"},{"key":"2023110719165154200_jiad251-B2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The biology of the HIV-1 latent reservoir and implications for cure strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2023110719165154200_jiad251-B3","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1172\/JCI138099","article-title":"HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus","volume":"130","author":"Halvas","year":"2020","journal-title":"J Clin Invest"},{"key":"2023110719165154200_jiad251-B4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/135965350200700203","article-title":"Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts","volume":"7","author":"Fischer","year":"2002","journal-title":"Antivir Ther"},{"key":"2023110719165154200_jiad251-B5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"2023110719165154200_jiad251-B6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/COH.0000000000000242","article-title":"Role of immune activation in progression to AIDS","volume":"11","author":"Utay","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2023110719165154200_jiad251-B7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: International AIDS Society global scientific strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat Med"},{"key":"2023110719165154200_jiad251-B8","doi-asserted-by":"crossref","first-page":"eaap9927","DOI":"10.1126\/scitranslmed.aap9927","article-title":"HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing","volume":"10","author":"Yukl","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023110719165154200_jiad251-B9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12977-015-0159-3","article-title":"Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis","volume":"12","author":"Campos","year":"2015","journal-title":"Retrovirology"},{"key":"2023110719165154200_jiad251-B10","first-page":"820","article-title":"Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects","volume":"72","author":"Scherrer","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023110719165154200_jiad251-B11","doi-asserted-by":"crossref","first-page":"e01288-16","DOI":"10.1128\/AAC.01288-16","article-title":"Randomized trial of food effect on pharmacokinetic parameters of ABX464 administered orally to healthy male subjects","volume":"61","author":"Scherrer","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110719165154200_jiad251-B12","doi-asserted-by":"crossref","first-page":"e00545-17","DOI":"10.1128\/AAC.00545-17","article-title":"Safety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled study","volume":"61","author":"Steens","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110719165154200_jiad251-B13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S2055-6640(20)30273-9","article-title":"Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a phase IIa randomised controlled study","volume":"5","author":"Rutsaert","year":"2019","journal-title":"J Virus Erad"},{"key":"2023110719165154200_jiad251-B14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41598-018-37813-y","article-title":"Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing","volume":"9","author":"Vautrin","year":"2019","journal-title":"Sci Rep"},{"key":"2023110719165154200_jiad251-B15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fimmu.2016.00406","article-title":"miRNA-124 in immune system and immune disorders","volume":"7","author":"Qin","year":"2016","journal-title":"Front Immunol"},{"key":"2023110719165154200_jiad251-B16","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1038\/s41598-017-04071-3","article-title":"The anti-HIV candidate Abx464 dampens intestinal inflammation by triggering il-22 production in activated macrophages","volume":"7","author":"Chebli","year":"2017","journal-title":"Sci Rep"},{"key":"2023110719165154200_jiad251-B17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1053\/j.gastro.2021.02.054","article-title":"Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIa trial","volume":"160","author":"Vermeire","year":"2021","journal-title":"Gastroenterology"},{"key":"2023110719165154200_jiad251-B18","doi-asserted-by":"crossref","first-page":"e0175899","DOI":"10.1371\/journal.pone.0175899","article-title":"Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue","volume":"12","author":"Mor\u00f3n-L\u00f3pez","year":"2017","journal-title":"PLoS One"},{"key":"2023110719165154200_jiad251-B19","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/QAD.0000000000000374","article-title":"Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients","volume":"28","author":"Puertas","year":"2014","journal-title":"AIDS"},{"key":"2023110719165154200_jiad251-B20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/cid\/civ456","article-title":"Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy","volume":"61","author":"Mart\u00ednez-Bonet","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023110719165154200_jiad251-B21","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/cid\/ciab733","article-title":"ABX464 decreases the total human immunodeficiency virus (HIV) reservoir and HIV transcription initiation in CD4+ T cells from antiretroviral therapy\u2013suppressed individuals living with HIV","volume":"74","author":"Moron-Lopez","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023110719165154200_jiad251-B22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jix039","article-title":"Human immunodeficiency virus persistence and T-cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy","volume":"215:","author":"Khoury","year":"2017","journal-title":"J Infect Dis"},{"key":"2023110719165154200_jiad251-B23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1086\/656722","article-title":"Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy","volume":"202","author":"Yukl","year":"2010","journal-title":"J Infect Dis"},{"key":"2023110719165154200_jiad251-B24","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/374786","article-title":"T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus\u2013infected patients with sustained viral suppression during antiretroviral therapy","volume":"187","author":"Hunt","year":"2003","journal-title":"J Infect Dis"},{"key":"2023110719165154200_jiad251-B25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"2023110719165154200_jiad251-B26","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.drudis.2020.12.019","article-title":"Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases","volume":"26","author":"Tazi","year":"2021","journal-title":"Drug Discov Today"},{"key":"2023110719165154200_jiad251-B27","doi-asserted-by":"crossref","first-page":"S014","DOI":"10.1093\/ecco-jcc\/jjy222.020","article-title":"OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients","volume":"13","author":"Vermeire","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2023110719165154200_jiad251-B28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"ABX464 (obefazimod) for moderate to severe active ulcerative colitis: a randomised, placebo-controlled phase 2b induction trial and 48-week extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023110719165154200_jiad251-B29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/annrheumdis-2022-222228","article-title":"Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and\/or anti TNF\u03b1 therapy: a placebo-controlled phase II study","volume":"81","author":"Daien","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023110719165154200_jiad251-B30","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1523\/JNEUROSCI.3474-17.2018","article-title":"Epigenetic promoter DNA methylation of miR-124 promotes HIV-1 tat-mediated microglial activation via MECP2-STAT3 axis","volume":"38","author":"Periyasamy","year":"2018","journal-title":"J Neurosci"},{"key":"2023110719165154200_jiad251-B31","doi-asserted-by":"crossref","DOI":"10.1177\/2516865718806904","article-title":"Involvement of epigenetic promoter DNA methylation of miR-124 in the pathogenesis of HIV-1\u2013associated neurocognitive disorders","volume":"11","author":"Buch","year":"2018","journal-title":"Epigenetics Insights"},{"key":"2023110719165154200_jiad251-B32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ebiom.2019.07.027","article-title":"Inflammatory and immunometabolic consequences of gut dysfunction in HIV: parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities","volume":"46","author":"Alzahrani","year":"2019","journal-title":"EBioMedicine"},{"key":"2023110719165154200_jiad251-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v13091751","article-title":"The splice of life: does RNA processing have a role in HIV-1 persistence?","volume":"13","author":"Pasternak","year":"2021","journal-title":"Viruses"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad251\/50907918\/jiad251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/9\/1280\/52789617\/jiad251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/9\/1280\/52789617\/jiad251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T14:36:47Z","timestamp":1699367807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/9\/1280\/7217079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,7,3]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad251","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,7,3]]}}}